Pyxis Oncology is trading 6.4% up at $3.99, with the move most likely reflecting continued biotech-sector momentum.
- It gained 9.01% on September 2, 2026; no new company-specific announcement or earnings release was identified overnight.
- The September 1 investor-conference announcement remains supportive, but is not a new September 3 catalyst; XBI rose 2.75% in the prior session.
- Broader markets are only modestly higher, making sector strength more relevant than global risk appetite.